Background: Improved knowledge of the molecular pathophysiology and immunopathogenesis of cholestatic liver diseases in recent years has led to an increased interest in developing novel therapies. Patients with cholestatic liver disease often require different approaches to assessment and management of suspected drug-induced liver injury (DILI) compared to those with healthy livers and those with parenchymal liver diseases. At present, there are no regulatory guidelines or society position papers, that systematically address best practices pertaining to detection of DILI in these patients.
| INTRODUC TI ON
Cholestatic liver diseases comprise many conditions of dysfunctional bile flow and/or formation, which can lead to progressive hepatobiliary damage and its complications. While the primary pathogenic mechanisms are yet to be fully elucidated, improved knowledge of the molecular and cellular pathophysiology and immunopathogenesis of cholestatic liver diseases in recent years has led to a resurgence of interest to develop new therapies. As such, a number of drugs, some of which are novel, are currently undergoing clinical evaluation. This increase in clinical development programs for cholestatic liver diseases. has brought to light the fact that there are numerous challenges faced in detecting, assessing, and managing suspected acute drug-induced liver injury (DILI) occurring during these trials (Box 1). To start with, the literature surrounding drug DILI occurring in patients with underlying cholestatic liver diseases is scarce. There are no regulatory guidelines or society position papers that systematically address best practices pertaining to detection of DILI in these patients.
Furthermore, patients with these conditions likely require different approaches to the assessment and management of suspected DILI, compared to patients with normal livers, or patients with parenchymal liver diseases such as viral hepatitis or non-alcoholic steatohepatitis (NASH). Thus, standard liver biochemical monitoring and stopping rules in the face of acute drug-associated liver injury may not be applicable to those with underlying cholestatic diseases. As there are a growing number of clinical trials assessing drugs for the treatment of cholestatic liver diseases, there is a great unmet need for consistent, evidence-based recommendations for best practices pertaining to suspected DILI in such patients. This consensus paper focuses on best practices for detection, assessment, and management of suspected acute DILI occurring during clinical trials in adults with cholestatic liver diseases.
The IQ DILI Initiative was launched in June 2016 within the International Consortium for Innovation and Quality in Pharmaceutical Development (also known as the IQ consortium) to reach consensus and propose best practices on topics related to clinical DILI. 1 The IQ Consortium is a science-focused, not-for-profit organisation addressing scientific and technical aspects of drug development and is comprised of 38 pharmaceutical and biotechnology companies. The IQ DILI Initiative is an affiliate of the IQ Consortium, comprised of 17 IQ member companies, focused on establishing best practices for monitoring, diagnosing, managing, and preventing DILI. This publication is based on an extensive literature review, and the consensus achieved in carefully structured discussions between IQ DILI members and academic and regulatory experts. The recommendations are based on the opinions of the authors, and do not imply a regulatory guidance or mandate. This paper will be limited to a discussion of detection, assessment and management of acute hepatocellular and cholestatic DILI in adults with Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) without advanced liver disease (Child Pugh B, and C) who are participating in clinical trials. Due to the scarcity of data in the published literature, other types of acute DILI and chronic forms of DILI (eg, vanishing bile duct syndrome or nodular regenerative hyperplasia) will not be discussed in this paper. However, it is strongly recommended that drug developers and investigators remain mindful of these less common types of DILI that could arise during drug development. While a complete discussion of the detection, assessment and management of DILI occurring in patients with paediatric cholestatic liver diseases is beyond the scope of this paper, there are many salient features specific to these patients which will be briefly addressed. Finally, a discussion of causality assessment is beyond the scope of this publication and will not be addressed in detail. A full discussion of Box 1 Key Challenges Faced in Detecting, Assessing, and Managing Suspected Acute Drug Induced Liver Injury (DILI) occurring During Clinical trials in Cholestatic Liver Diseases 1. The literature surrounding DILI occurring in patients with underlying cholestatic liver diseases is scarce.
2. It is unknown if patients with cholestatic liver disease have an increased susceptibility to DILI or worse outcomes when DILI occurs, compared with those with normal livers or patients with hepatocellular liver disease.
3. There are no regulatory guidelines or society position papers that systematically address monitoring and stopping criteria for patients with cholestatic liver disease who develop a hepatocellular or cholestatic DILI signal. 4 . Liver biochemical monitoring and stopping rules that are utilized for patients with normal livers or patients with hepatocellular liver disease may not be applicable to those with cholestatic liver diseases.
The upper limit of normal for alkaline phosphatase varies
among laboratories and some laboratories report separate upper limit of normal values for different sex and age groups. 6 . Cholestatic DILI may be indistinguishable from progression of the underlying cholestatic liver disease both clinically as well as histologically 7. biochemical tests often fluctuate in patients with PSC possibly due to intermittent blockage of strictured bile ducts by biliary sludge or small stones confounding evaluation for DILI. 8 . The natural course of PSC characteristically includes episodes of cholangitis which may mimic DILI biochemically, making detection and assignment of causality challenging. 9 . The optimal approach of applying Hy's Law in clinical trials in patients with cholestatic liver disease is still a matter of debate, and clear guidelines and definitions are lacking. 10 . Establishing liver biochemical test monitoring and stopping rules based solely on multiples of upper limit normal may result in inconsistent and/or incorrect evaluation of the hepatotoxicity of the candidate drug. these topics will be the focus of subsequent papers from the IQ DILI Initiative.
| DEFINING THE PAT TERN OF D ILI IN PATIENTS WITH CHOLE S TATIC LIVER DISE A SE
The three predominant patterns of liver blood test elevations used to differentiate and classify the types of DILI are hepatocellular, cholestatic and mixed. The international criteria for liver toxicity, established by the Council of International Organizations of Medical Sciences (CIOMS) in 1990, defined the pattern of liver injury by using an R value, 2, 3 The ratio is ≥5 in acute hepatocellular injury, <2 in cholestatic liver injury, and between 2 and 5 in mixed hepatocellular-cholestatic liver injury. 2, 3 However, it has been recommended that for patients with underlying liver disease and baseline abnormal hepatic biochemical indicators, R values derived from serum test results at the peak of acute drug-associated liver injury should be calculated using the mean baseline values obtained prior to exposure to the suspect drug, instead of the ULN. 4 This should then be compared with the R value after drug exposure. It should be emphasised that the utility of the R value in patients with underlying cholestatic liver disease has not been defined or systematically evaluated and therefore, needs to be established.
| CONSENSUS RECOMMENDATIONS 1 & 2
1. The utility of the R value in patients with cholestatic liver disease has not been demonstrated and therefore, needs to be established 2. If the R value is used to define the pattern of DILI in patients with PBC or PSC, it is recommended that the R value of the suspected event be compared to the baseline R value of the underlying disease, although the significance of a shift from the baseline value has not been assessed, and therefore, needs to be established.
| ARE PATIENTS WITH CHRONI C CHOLE S TATI C LIVER D IS E A S E AT IN CRE A S ED RIS K FOR D ILI?
Experts in the field of DILI generally consider that patients with underlying chronic liver disease, do not appear to have an increased susceptibility for DILI compared with those patients without chronic liver disease. [5] [6] [7] However, should DILI occur, patients with chronic liver disease have an increased incidence of morbidity and mortality compared with those with healthy livers. [7] [8] [9] Of note, patients with PBC and PSC were excluded in the drug-induced liver injury network (DILIN) studies, 8, 10 and thus, findings from the drug-induced liver injury network may not be applicable to patients with cholestatic liver disease. Finally, two studies noted cases of an increased likelihood of hepatotoxicity when rifampicin was given to patients with PBC to treat pruritus 11, 12 compared to the incidence reported when rifampicin was given to those without underlying chronic liver disease noted in other studies. 13 These studies were not placebo-controlled and consisted of case reports or retrospective chart reviews. Thus, a definitive conclusion as to the increased risk of hepatotoxicity due to rifampicin in patients with PBC cannot be drawn.
| CONSENSUS RECOMMENDATIONS 3-6
3. It is unknown if patients with chronic cholestatic liver disease have an increased susceptibility to DILI 4. The outcome of DILI in patients with cholestatic liver disease has not been specifically studied, but until proven otherwise, it is a good practice to consider that acute DILI occurring in patients with cholestatic liver diseases, especially those with advanced liver disease, is associated with worse outcomes.
5.
Studies are needed to evaluate if patients with cholestatic liver diseases are more susceptible to DILI than those with normal livers, or patients with hepatocellular liver disease.
Studies are needed to evaluate if DILI occurring in patients with
cholestatic liver diseases is associated with worse outcomes
| PRIMARY B ILIARY CHOL ANG ITIS
PBC is a chronic autoimmune cholestatic liver disease in which the small and medium-sized intrahepatic bile ducts are the target of destruction leading to cholestasis, portal inflammation, fibrosis and cirrhosis. 14, 15 The diagnosis of PBC is made when two of the following are present: an elevated ALP, a positive antimitochondrial antibody (AMA) and/or consistent liver histology. 15, 16 Prevalence is estimated at 1.9 to 40.2 per 100 000 people. 17 Approximately 90% are Caucasian women, and the median age at presentation is 52 years. [17] [18] [19] While the rate of disease progression may vary individually, PBC is characterised by a slow steady progression occurring over many decades. 15 With the approval of ursodeoxycholic acid in 1997, the natural history of PBC has improved and this drug remains a first line treatment for PBC. [20] [21] [22] [23] Up to 40% of ursodeoxycholic acid-treated patients have persistently elevated ALP levels which have been associated with reduced transplant-free survival. 22, [24] [25] [26] Obeticholic acid was approved in 2016 to be used in combination with ursodeoxycholic acid for those patients who have an inadequate response to ursodeoxycholic acid alone or as monotherapy for those patients intolerant to ursodeoxycholic acid 0. 27, 28 Other drugs with varied mechanisms of action are currently in development with the goal of expanding treatment options, improving response rates and prolonging survival. [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] where R = (alanine aminotransferase ALT ∕upper limit normal ULN alkaline phosphatase ALP ∕ULN
| HEPATI C ELI G IB ILIT Y CRITERIA FOR PATIENTS WITH PBC
As is characteristic of all cholestatic liver diseases, the degree of ALP elevation is higher than the degree of aminotransferase elevation in PBC. ALP typically ranges from 2 to approximately 10 x ULN, although ALP may be normal in the early stages of disease. [42] [43] [44] [45] [46] While mean ALP values most commonly range between 2-3 × ULN, 27, 44, 47 a recent study from Mexico comparing survival rates of patients treated with ursodeoxycholic acid compared with other treatments, reported that entry ALP prior to the start of either ursodeoxycholic acid or other drugs was 5.2 ± 3.7 × ULN and 4.0 ± 4.5 × ULN (mean ± SD) in the two groups respectively. 43 disease. In addition, ALP can only be used as an endpoint if the drug mechanism of action is in the pathway of ALP production.
An upper limit for ALP exclusion has typically not been specified in PBC clinical trials. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] Since it is rare for patients with PBC to have an ALP >10× ULN, it seems prudent to exclude these patients from trial participation, especially in early phase trials (phase 1 and 2 ALP may originate from tissues other than the liver, most commonly from bone. 49 Thus, gamma glutamyl transferase (GGT) and/ or ALP fractionation to determine the percent derived from the liver isoenzyme versus bone or another nonliver origin, is important to determine baseline levels. For example, elevated ALP may be of bone origin in post-menopausal women who have osteoporosis and bone turnover. 50 Thus, baseline isoenzyme identification and/or GGT will prove useful during causality assessment if ALP elevations occur during the clinical trial.
Aminotransferases are often elevated, but are usually <3× ULN, and as such, some PBC clinical trials excluded patients with aminotransferases >3× ULN. 21, 42, 47, [51] [52] [53] [54] [55] [56] [57] Since the diagnosis of PBC does not require a liver biopsy in the setting of a positive antimitochondrial antibody, an ALP >1.5× ULN and an AST ≤5 times normal, 15, 58 most trials have defined aminotransferase levels >5× ULN as an exclusionary criterion. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] 
| MONITORING OF LIVER TE S TS AND D ILI DE TEC TI ON IN PBC CLINI C AL TRIAL S
Studies from the pre-ursodeoxycholic acid era demonstrated that PBC progresses slowly and steadily over many decades, without significant fluctuations in ALP or aminotransferase levels, however, as disease progresses total bilirubin may elevate. [65] [66] [67] [68] [69] 
| OB E TI CHOLI C ACID AND P OTENTIAL HEPATOTOXI CIT Y
Adherence to instructions outlined in the clinical trial protocol, as well as the prescribing regimen detailed in the approved product label to modify study drug dosing or avoid treatment altogether in the presence of defined liver abnormalities remains an important aspect for preventing DILI in patients with chronic liver disease. 70 This is underscored by the recent incidence of liver-related adverse events occurring in patients with PBC who were prescribed obeticholic acid (Ocaliva ® )a farnesoid X receptor (FXR) agonist. Approximately 15 months after regulatory approval, a warning letter was sent to healthcare practitioners concerning 19 deaths and 11 cases of serious liver injury that occurred post-approval in patients with PBC taking obeticholic acid. 71 On February 1, 2018, the FDA concluded that most, although not all, of these patients had advanced liver disease (Child Pugh B or C) and were dosed more frequently than the recommended dose as detailed in the drug label for patients with advanced liver disease. 72, 73 This resulted in a label update adding a boxed warning alerting that hepatic decompensation and failure have been reported in patients with PBC with decompensated cirrhosis or Child
Pugh class B or C, who were incorrectly dosed. 28 Obeticholic acid has now been listed on livertox.nih.gov as "a suspected rare cause of clinically apparent liver injury occurring mostly in patients with preexisting cirrhosis"0. 74 In reviewing published clinical trials of obeticholic acid for PBC, it is noted that there were discontinuations due to elevated liver tests, although the profiles of these patients were not publicly available for evaluation. 27, 42, 47 While monitoring and stopping criteria were also unable to be located within these publications or supplemental appendices for review, a joint lecture from the American Association for the Study of Liver Disease (AASLD) and FDA in 2016 75 listed ALT and/or AST >3× ULN and 2× baseline or two consecutive tests of total bilirubin >ULN and 2× baseline in the absence of biliary obstruction, as the stopping criteria for obeticholic acid clinical trials for PBC. Pooled results from three PBC placebo-controlled trials revealed that liver-related adverse events were more common in subjects receiving obeticholic acid compared with those on placebo. 76 The mechanism of action of potential obeticholic acid hepatotoxicity is unknown. 77 A case report of a patient with Child Pugh A cirrhosis due to PBC who developed clinical and histologic cholestatic hepatitis two months after stopping a higher than recommended dose of ursodeoxycholic acid (23mg/kg) and simultaneously starting obeticholic acid has recently been reported. 78 The authors of this article postulated that this event was triggered by an increase in hydrophobic bile acids in addition to a reduction in bile flow, leading to cholestatic hepatitis. In the phase 2 obeticholic acid study in patients with PBC and an inadequate response to ursodeoxycholic acid, Hirschfield and colleagues reported jaundice The specific interval between tests should also be determined based on the patient's clinical condition. d The study subject will require close follow-up monitoring to exclude recurrence of liver injury after restarting the study drug.
in two patients. 27 While the fibrosis stage of these patients was not stated in the publication, a similar mechanism of action might be postulated as these patients were on a higher dose (50mg) of obeticholic acid then ultimately recommended for patients with The study subject will require close follow-up monitoring to exclude recurrence of liver injury after restarting the study drug. 19 . Dose adjustment recommendations as stated in the obeticholic acid (Ocaliva ® ) product label should be followed in any clinical trial that is investigating obeticholic acid as part of a combination therapy.
| CONSENSUS RECOMMENDATIONS 19-21

Patients entering clinical trials utilising obeticholic acid or
any of the newer farnesoid X receptor agonists who have advanced liver disease or patients determined to have progressed to advanced liver disease during the course of the trial, should be monitored on a more frequent basis to evaluate for signs of hepatic decompensation, than patients in early stages of disease.
21.
To determine whether subjects with advanced liver disease have been optimally dosed with any study drug that undergoes hepatobiliary clearance, a pharmacokinetic analysis of the parent compound and its metabolites should be performed.
| US E OF NE W NAD IR LIVER VALUE S AND S TOPPING RULE S IN PBC CLINI C AL TRIAL S
While HCV, being a hepatocellular disease, and PBC, being a cholestatic disease, differ significantly, some lessons learned from HCV drug development can be applied to drug development for new PBC therapies. In particular, since it was noted that normalisation or significant reductions of ALT values occurred within the first few weeks of direct acting antiviral therapy for HCV, 79 it was recommended that this new ALT nadir value be used instead of baseline ALT levels, to evaluate potential DILI. [80] [81] [82] As such, an elevation of ALT and/or AST >5× baseline or >5× the nadir value occurring early after treatment initiation, was used to trigger drug discontinuation in some HCV trials. 79, 83 In The specific interval between tests should also be determined based on the patient's clinical condition. d The study subject will require close follow-up monitoring to exclude recurrence of liver injury after restarting the study drug.
ALP were achieved and stabilised by 1-3 months of therapy. 27, 42, 47, 51, 54 Although not assessed in any trials, the degree of reduction in ALT and ALP to achieve this nadir value was approximately a mean reduction of 15% from baseline value. 27, 47, 51, 54 Of note, this reduction is not as steep and impressive as the reduction of ALT achieved in HCV trials in response to therapy which triggered the nadir recommendation. 79, 81, 82 While total bilirubin levels also decrease in response to therapy, change from baseline is mild due to the fact that most subjects enter PBC trials with a total bilirubin < 2 gm/dL. 27, 42, 47, 51, 52 Algorithms for monitoring, interrupting and stopping drug for the management of patients with PBC in clinical trials are illustrated in Tables 1-3 However, the specific interval between the tests should also be shortened if the patient's clinical condition warrants a rapid response by the investigator.
| S PECIAL CON S IDER ATI ON S FOR C AUSALIT Y A SS E SS MENT OF P OTENTIAL D ILI E VENTS IN PATIENTS WITH PBC
Causality assessment in patients with PBC participating in a clinical trial can be challenging. While a full discussion is beyond the scope of this paper, a few points specific to PBC will be discussed. When elevated liver biochemistries occur during a PBC clinical trial, it is also important to rule out the onset of PBC/autoimmune hepatitis overlap syndrome. Clues that a patient may have developed an overlap syndrome includes a new rise in ALT >5× ULN, which is uncommon for PBC alone. 59, 84, 85 An immunoglobulin G >2× ULN and/or anti-smooth muscle antibody titre >1:80 is characteristic of overlap syndrome and these tests should be obtained for evaluation to assist in differentiating from potential DILI. As drugs are known potential triggers for idiopathic autoimmune hepatitis, it is important to be aware that DILI can also be associated with high antinuclear antibody and anti-smooth muscle antibody titres, as well as high immunoglobulin G levels. [85] [86] [87] [88] [89] In addition, there is also a subset of autoimmune hepatitis known as drug-induced autoimmune hepatitis, in which patients had pre-existing undiagnosed low grade disease and/ or a genetic predisposition to autoimmune hepatitis which becomes overt after being triggered by a drug. 85, 86 Since a considerable degree of histologic overlap exists between all of these types of autoimmune liver disease, a liver biopsy may reveal characteristics that can distinguish idiopathic autoimmune hepatitis from DILI. 90 Finally, 26 . PBC/autoimmune hepatitis overlap syndrome, as well as idiopathic autoimmune DILI should be considered as potential causes for the new onset of elevated liver biochemistries. However, it must be kept in mind that a new-onset overlap syndrome could be drug-induced.
| CONSENSUS RECOMMENDATIONS 26-28
27.
A liver biopsy should be considered as part of causality assessment as it may provide clues that assist in differentiating autoimmune hepatitis from DILI. The possible need for a liver biopsy to determine causality or to assist with the clinical management of a case of concern, should be addressed in the protocol, as well as the informed consent.
28. Additional causes of clinically significant abrupt elevations in liver blood tests including, but not limited to, acute and chronic viral hepatitis (hepatitis A-E), cholelithiasis and alcohol, other drugs both prescribed and over-the-counter herbs and supplements, should be also ruled out.
| PRIMARY SCLEROS ING CHOL ANG ITIS
Primary sclerosing cholangitis (PSC) is an idiopathic, cholestatic liver disease characterised by extra and/or intra hepatic biliary tract inflammation and destruction that can lead to end-stage liver disease and its complications including cholangiocarcinoma. [91] [92] [93] PSC is more common in men than in women with 2:1 ratio, is associated with IBD in up to 80% of cases, has a peak incidence around 40 years of age and has a prevalence estimate of up to 16.2 per 100 000 people. 17, 92 Diagnosis is made when an elevated ALP is found in association with characteristic cholangiographic (eg, magnetic resonance cholangiography, endoscopic retrograde cholangiography) findings of multifocal strictures and dilatations of bile ducts, and secondary causes of sclerosing cholangitis have been excluded. 94, 95 A liver biopsy is not required for diagnosis in patients with characteristic cholangiographic findings, but is useful when atypical liver tests are present in order to diagnose small duct PSC or to rule out other aetiologies, particularly overlap syndrome. [94] [95] [96] Aetiology is unknown but likely multifactorial, and includes, but is not limited to influences related to genetic factors, the environment, immunity, gut-lymphocyte homing and toxic bile acids. 97 Higher doses of ursodeoxycholic acid at 28 to 30 mg/kg/d have been associated with an increased mortality compared with placebo. 84 Although commonly used off-label at a dose of ~ 20 mg/kg/d, 96 there has not been a definitive recommendation in society guidelines endorsing the use of ursodeoxycholic acid in the treatment for PSC, 95, 96 although ursodeoxycholic acid in doses of > 28 mg/ kg/day is not advised. 96 The natural history of PSC is highly variable and needs to be studied in further detail. Its course is characteristically marked by fluctuating hepatic blood tests, symptoms and bouts of cholangitis. [99] [100] [101] Thus, determining the aetiology of abrupt elevations in liver biochemistries and differentiating an episode of acute cholangitis from DILI in patients with PSC can be challenging.
| HEPATI C ELI G IB ILIT Y CRITERIA FOR PATIENTS WITH PSC
Hepatic biochemical tests in PSC typically indicate cholestasis, with the most common biochemical abnormality being elevated ALP. Baseline ALP values from published clinical trials ranged from 1.5-10× ULN, with a mean ranging between 2-4× ULN. 42, 84, [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] However, ALP may be normal 112, 113 or during an episode of cholangitis can be ≥10x ULN. 93, 94 Inclusion criteria of ALP for eligibility into PSC treatment trials have included a lower limit ranging from 1.5-2× ULN 114-124 without specification of an upper limit for exclusion. Since levels of ALP >10× ULN rarely occur during disease progression in the absence of acute cholangitis, it is reasonable to set this as the upper limit for exclusion criteria. Confirming stability and setting an upper limit of ALP for exclusion, will likely improve diagnostic accuracy and eliminate enrolling patients with ongoing biliary complications. However, since there are no validated markers of disease activity, differentiating between a PSC flare occurring during treatment and potential cholestatic DILI remains challenging.
Repeat liver test measurements to determine the stability of two ALT measurements to determine baseline levels, and if a major difference (ie >50%) existed between the two tests, a third test was recommended to determine the degree and direction of the change. 125 As ALP often fluctuates, it is prudent to repeat this measurement to confirm stability prior to the start of study medication. Subjects in the AESOP trial, a phase 2 study testing obeticholic acid in PSC, who received placebo, experienced a mean ALP reduction of 9% from baseline which likely represented normal ALP fluctuation in PSC. This was in comparison to subjects on obeticholic acid who achieved a 31% ALP reduction from baseline after 24 weeks. 126 While obtaining serial ALP measurements to establish baseline levels has not as yet been routinely adopted, one trial required that the ALP did not fluctuate >15% in the past 3 months prior to enrolment. 127 104, [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] As such, most baseline total bilirubin levels in published clinical trials of treatment for PSC have been normal or slightly abnormal. 42, 84, [103] [104] [105] [106] [107] [108] 110 Aminotransferase levels are elevated in the majority of patients (2-5× ULN) but can also be in the normal range. However, peak aminotransferase levels are rarely above 300 U/L. 93, 128, 129 As opposed to the relative consistency of ALP and total bilirubin levels set for inclusion criteria among different PSC clinical trials listed on clinical trials.gov, there has been a wide variance of aminotransferase levels listed for eligibility criteria ranging from <5× ULN to <10× ULN. 95, [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] 130 The prevalence of autoimmune hepatitis in patients with PSC ranges between approximately 2% and 17%. 92, 96, 131 These patients typically have aminotransferases >5× ULN, underscoring the need to have an upper limit threshold for aminotransferases for trial eligibility. It is also important to remember that, antinuclear antibody, antismooth muscle antibody and antineutrophil cytoplasmic antibodies are common in patients with PSC. 93, 111, 132, 133 Patients with other co-incident chronic liver diseases, such as HBV, 
| SPECIAL CONSIDERATIONS FOR CAUSALITY ASSESSMENT OF POTENTIAL DILI EVENTS IN PATIENTS WITH PSC WITHOUT ADVANCED CIRRHOSIS (CHILD PUGH B, C)
The 
| MONITORING OF LIVER B I O CHEMIS TRIE S AND D ILI DE TEC TI ON IN PSC CLINIC AL TRIAL S
Monitoring and stopping rules for liver test elevations from PSC clinical trials and publications were not readily located in the public domain for review. Suggested algorithms (Tables 1-3 There is no single definitive prognostic biomarker for measuring PSC disease progression and there is a lack of consensus over clinically relevant endpoints in PSC clinical trials. However, ALP is the most commonly utilised surrogate biomarker and as such, is typically the primary endpoint in most early phase PSC treatment trials. [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] 139 Thus, a reduction of ALP has been utilised as an indicator of treatment response and has been noted to occur by week 12 in many trials and as early as week 4 of treatment in some. 42 However, the specific interval between the tests should also be based on the patient's clinical condition.
| CHOLE S TATI C D ILI
Cholestatic liver injury is responsible for ~ 20%-40% of all DILI cases, although older patients (≥60 years) may be more prone to cholestatic DILI comprising up to 61% of compiled cases. [140] [141] [142] Elevated baseline ALP due to the underlying cholestatic liver disease, makes it particularly challenging to diagnose cholestatic DILI in this patient population.
When worsening cholestasis occurs during a clinical trial of PBC or PSC, cholestatic DILI is typically indistinguishable from progression of the underlying cholestatic liver disease both clinically as well as histologically. 143, 144 The use of ALP ≥2× ULN as the threshold to identify the cholestatic pattern of liver injury 2,3 would not be appli- year. In comparison, hepatocellular DILI typically occurs from 2 to 24 weeks from start of drug with occurrence unlikely after 52 weeks or sooner than 4 days after drug initiation. 145 Furthermore, time course for improvement with cholestatic injury is typically slower than for hepatocellular injury. 143 The source of the ALP elevation should be confirmed as originating from the liver or biliary tract by obtaining a GGT or by fractionating ALP and assessing any change from baseline. It should be noted that increases in GGT occur earlier and persist longer than ALP in cholestatic disorders. 146 GGT levels can be elevated due to other conditions, such as alcohol ingestion or other causes of enzyme induction. 147 As GGT will typically already have been determined to be elevated, ALP fractionation to obtain individual isoenzymes may be useful and should be measured when the aetiology of treatment emergent ALP elevations are unclear.
While blood tests typically return to baseline within 6 months after drug interruption, cholestatic DILI can lead in rare instances to vanishing bile duct syndrome 0. [148] [149] [150] Vanishing bile duct syndrome is a serious disease and may cause biliary fibrosis, cirrhosis and decompensated liver disease. Histologically, it can mimic PBC increasing the complexity of causality assessment.
| ADDITIONAL CONS IDER ATIONS FOR CLINI C AL TRIAL S OF PBC AND PSC
As between 5%-10% of the population has Gilbert's Syndrome, it is likely that some patients enrolled in a cholestatic liver disease trial will also have this hereditary condition characterised by intermittent unconjugated (indirect) hyperbilirubinaemia in the absence of hepatocellular disease. 151, 152 Total bilirubin levels in Gilbert's Syndrome are usually mildly elevated, but rarely greater than 4-5 mg/dL. 153, 154 Gilbert's Syndrome is caused by a reduction of the level of the enzyme uridine 5'-diphospho--glucuronyl-transferase to 20-30% of its normal amount which results in impaired conjugation of bilirubin with glucuronic acid. 151 It is important to accurately identify Gilbert's Syndrome in clinical trials, especially clinical trials in cholestatic liver diseases, as misdiagnosis may result in unnecessary diagnostic testing, incorrect assignment of causality, as well as drug interruption or discontinuation. Diagnosis is confirmed by calculating the amount of conjugated bilirubin, which should be less than 20%-30% of the total bilirubin, in the absence of haemolysis. 155, 156 It should be noted that the terms "direct" and "conjugated" hyperbilirubianemia, are regularly, yet incorrectly, used interchangeably. Direct bilirubin includes both the conjugated fraction, as well as delta bilirubin, which is bound to albumin, and thus, has a half-life of approximately 21 days.
It is the presence of delta bilirubin that causes direct hyperbilirubinaemia to persist. 157 If the aetiology of prolonged hyperbilirubinaemia is uncertain, a breakdown of the direct bilirubin fraction to conjugated and delta bilirubin should be considered.
When hyperbilirubinaemia is due to DILI, the fraction of direct bilirubin should be measured, and is usually greater than 35%. 81 When the diagnosis is unclear, genetic testing for DNA mutations of uridine 5'-diphospho--glucuronyl-transferase should be considered. 158 162 This can occur independent of the HBsAb status. 163 Thus, HBV could be reactivated when the immune system is suppressed by immunomodulatory therapy. 164 
| ALGORITHM FOR MONITORING AND MANAG EMENT OF P OSS IB LE HEPATO CELLUL AR OR CHOLE S TATI C D ILI IN PBC AND PSC CLINI C AL TRIAL S IN PATIENTS WITH NORMAL OR ELE VATED BA S ELINE ALT
Hy's law identifies hepatotoxic drugs with a potential to cause idiosyncratic severe hepatocellular liver injury. 7, 165, 166 In patients with- 58. In clinical trials of patients with underlying cholestatic liver disease, using the baseline ALT value or new nadir level and a combination of multiples of ULN, in conjunction with an elevated bilirubin, may lead to a more accurate assesment of drugs with hepatotoxic potential to cause idiosyncratic severe hepatocellular liver injury, as opposed to applying the current criteria for Hy's law.
| CONSENSUS RECOMMENDATIONS 58
| PAED IATRI C CHOLE S TATI C LIVER DISE A SE
A comprehensive review of assessment and monitoring of DILI in paediatric cholestatic liver diseases is beyond the scope of this paper. There is great interest in developing novel therapies for paediatric cholestatic liver diseases, many of which have an urgent unmet medical need. As such, clinical trials for many of these diseases with varied pharmacologic interventions are ongoing and more are under consideration. 168 A full discussion of this topic will be the focus of a subsequent paper from the IQ DILI Initiative. However, a few salient points will be mentioned. Significant limitations on the existing natural history data, include lack of information surrounding the range and fluctuations of common liver biochemical tests over short periods of time with these conditions. These shortcomings make recommendations about DILI monitoring and intervention in paediatric cholestatic liver diseases difficult. Notably, biochemical criteria of hepatotoxicity in adults with cholestatic disease may not apply to paediatric populations due to development-related differences in 10. An episode of DILI resulting in hepatic decompensation should trigger permanent drug discontinuation.
the normal ranges of common liver tests including total bilirubin, aminotransferases, and ALP from early infancy through the pubertal growth spurt. In addition, certain hereditary cholestatic liver diseases in infants and children are not associated with the characteristic rise in GGT that are seen in PBC or PSC and cannot be relied upon as a marker of cholestatic injury. 169 During growth in normal paediatric study subjects, ALP levels are affected by fluctuations of the enzyme derived from bone. Changes of ALP in paediatric patients are also typically observed with vitamin D deficiency. Nutritional problems including fat soluble vitamin deficiency are very common and may be difficult to completely correct in paediatric cholestatic disease. 170 The clinical and biochemical course of the varied monogenic defects in bile secretion machinery that are uniquely seen in children are quite distinct from each other and thus need to be considered individually. As such, DILI monitoring and study drug stopping criteria designed for adult cholestatic liver diseases cannot simply be applied to paediatric cholestatic liver diseases. The ontogeny of intrahepatic enzymes and transporters also factor into the biochemical phenotype of infantile and early childhood paediatric cholestatic liver disease, another factor which needs to be considered in the development of guidelines for these study populations.
| CON CLUS ION
The number of drug development programs for cholestatic liver disease, particularly PBC and PSC, has grown considerably over the last few years. Patients with these diseases often require different approaches to suspected DILI detection, assessment and management. compared to patients with healthy livers or patients with parenchymal liver disease. This paper highlights the challenges faced and provides consensus recommendations for best practices on this topic based on collaborative work of the IQ DILI initiative and DILI experts from academia, and the Food and Drug Administration.
However, there are still many gaps to fill, and questions to be answered, underscoring the need for further research in this important and complex area. 
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